ADAP - Adaptimmune posts pre-clinical data from mesothelin cancer study

Adaptimmune Therapeutics (ADAP) posts preclinical data from the company's mesothelin HiT program demonstrating antigen-specific tumor cell killing in vitro and complete tumor regression in an animal model.The company's HLA-independent TCR targeting mesothelin induced complete regression in a mouse tumor xenograft model.The HLA-independent TCR or HiT platform enables the company to target extracellular proteins, such as those utilized by CAR or TRuC T-cell therapies.In the study, human T-cells expressing the mesothelin-targeted HiT kill human tumor cell lines and primary human lung tumor cells expressing mesothelin.Data demonstrate that the mesothelin HiT is not dependent on CD8 to kill target cells, and CD4 cells expressing the HiT are cytotoxic towards tumor cells.Shares up nearly 1% premarket.

For further details see:

Adaptimmune posts pre-clinical data from mesothelin cancer study